A clinical review of CBD for epilepsy: effectiveness, drug interactions, and regulatory challenges
CBD has better antiepileptic potential than THC and is FDA-approved for Dravet and Lennox-Gastaut syndromes, but it has significant drug-drug interactions and can cause liver enzyme elevation, especially with valproate.
Quick Facts
What This Study Found
CBD modulates multiple endogenous systems for anticonvulsant effects. It has broad drug interactions with CYP3A4 and CYP2C19 substrates. Liver enzyme elevation occurs especially when co-administered with valproate. FDA-approved pharmaceutical-grade CBD is expensive and schedule V, while other CBD products remain schedule I and unregulated.
Key Numbers
FDA approved for Dravet and Lennox-Gastaut syndromes. Drug interactions with CYP3A4 and CYP2C19 substrates. Liver enzyme elevation with valproate co-administration. Pharmaceutical CBD reclassified as schedule V.
How They Did This
Narrative review of CBD's clinical efficacy, mechanism of action, drug interactions, regulatory status, and practical challenges for epilepsy treatment.
Why This Research Matters
Many families are turning to CBD for epilepsy, but the practical reality is complicated by drug interactions, cost, regulatory inconsistency, and the risk of unregulated products.
The Bigger Picture
The gap between FDA-approved pharmaceutical CBD and the unregulated CBD market creates a two-tier system where patients who cannot afford or access the approved product may turn to products of unknown quality.
What This Study Doesn't Tell Us
Narrative review. Does not include its own meta-analysis. The exact anticonvulsant mechanism remains unknown.
Questions This Raises
- ?Will insurance coverage expand beyond Dravet and Lennox-Gastaut?
- ?Can unregulated CBD products achieve similar results?
- ?How should physicians manage drug interactions in patients already on multiple antiepileptics?
Trust & Context
- Key Stat:
- CBD causes liver enzyme elevation when combined with valproate
- Evidence Grade:
- Moderate: comprehensive clinical review of established evidence and regulatory landscape.
- Study Age:
- Published in 2019.
- Original Title:
- Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
- Published In:
- Pediatric neurology, 96, 24-29 (2019)
- Authors:
- Samanta, Debopam(2)
- Database ID:
- RTHC-02273
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is all CBD the same for epilepsy?
No. FDA-approved pharmaceutical-grade CBD (Epidiolex) has standardized dosing and quality control. Over-the-counter CBD products vary widely in purity, concentration, and may contain THC or contaminants.
What are the most important drug interactions?
CBD inhibits CYP3A4 and CYP2C19 enzymes, which metabolize many common medications. It can raise levels of some antiepileptic drugs and causes liver problems when combined with valproate.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02273APA
Samanta, Debopam. (2019). Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.. Pediatric neurology, 96, 24-29. https://doi.org/10.1016/j.pediatrneurol.2019.03.014
MLA
Samanta, Debopam. "Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.." Pediatric neurology, 2019. https://doi.org/10.1016/j.pediatrneurol.2019.03.014
RethinkTHC
RethinkTHC Research Database. "Cannabidiol: A Review of Clinical Efficacy and Safety in Epi..." RTHC-02273. Retrieved from https://rethinkthc.com/research/samanta-2019-cannabidiol-a-review-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.